Wilms Tumor

Wilms tumor, or nephroblastoma, is the most common primary renal malignancy in children and one of the great success stories of pediatric oncology — a disease that killed most affected children before the 1950s is now cured in more than 90% of patients through collaborative, protocol-driven treatment. Arising from embryonic kidney precursor cells, Wilms tumor teaches fundamental lessons about pediatric oncogenesis, the genetics of tumor suppressor genes, and the remarkable effectiveness of combining surgery, chemotherapy, and targeted radiotherapy in children. With approximately 500 new cases diagnosed annually in the United States, it remains the fourth most common pediatric malignancy overall.

Overview and Epidemiology
Genetics and Predisposing Syndromes
Pathology and Histology
Clinical Presentation
Diagnosis and Imaging
Staging
Treatment
Prognosis and Survival
Key Research Papers
PubMed Topic Searches
Connections
Featured Videos

1. Overview and Epidemiology

Wilms tumor (nephroblastoma) is the most common primary malignant tumor of the kidney in children, accounting for approximately 85–90% of all pediatric renal tumors and roughly 6% of all childhood cancers in the United States. About 500 new cases are diagnosed annually in the United States, translating to an incidence of approximately 7.6 cases per million children under 15 years of age.

The peak age of diagnosis is 3 to 4 years. The tumor is rare in the first six months of life — when it does occur in infants this young, genetic syndromes are more likely to be involved — and it becomes uncommon after age 15. Median age at diagnosis is approximately 44 months for unilateral tumors. Adult Wilms tumor exists but is rare, comprising less than 1% of adult renal malignancies, and generally carries a worse prognosis than the pediatric form.

Bilateral involvement occurs in approximately 5–10% of patients (Stage V disease). Bilateral tumors are more strongly associated with genetic predisposition syndromes, younger age at diagnosis, and nephrogenic rests. Managing bilateral Wilms tumor requires the additional imperative of preserving enough functional renal parenchyma to avoid dialysis dependence.

Sex distribution is roughly equal, with a slight female predominance in some series. There is a modest excess risk among children of African ancestry compared to Asian-ancestry children, with White and Black American children having similar rates. The disease occurs worldwide with relatively uniform incidence, unlike some adult cancers that show dramatic geographic variation tied to environmental exposures.

Before modern multimodality treatment, Wilms tumor was almost universally fatal. The National Wilms Tumor Study Group (NWTS), established in 1969 and succeeded by the Children's Oncology Group (COG), transformed outcomes through a series of landmark collaborative trials that progressively refined surgery, chemotherapy, and radiotherapy — achieving today's overall five-year survival exceeding 90%.

Back to Table of Contents

2. Genetics and Predisposing Syndromes

Wilms tumor arises through inactivation of tumor suppressor genes that regulate normal renal development. Approximately 10–15% of cases are associated with recognized genetic syndromes or constitutional mutations; the majority (~85%) are sporadic with no identifiable germline alteration at clinical evaluation, though somatic mutations accumulate during renal development.

WT1 Gene (11p13)

The WT1 gene on chromosome 11p13 encodes a zinc-finger transcription factor essential for normal kidney and gonadal development. Constitutional WT1 mutations or deletions underlie several overgrowth and genitourinary syndromes:

Denys-Drash syndrome: Caused by specific missense mutations in the zinc-finger DNA-binding domain of WT1. The triad consists of (1) diffuse mesangial sclerosis leading to nephrotic syndrome in infancy, (2) 46,XY male pseudohermaphroditism (ambiguous or female genitalia despite XY karyotype), and (3) Wilms tumor. Children with Denys-Drash syndrome have an approximately 90% lifetime risk of Wilms tumor and typically present at younger ages. Prophylactic nephrectomy is sometimes considered given the near-certainty of tumor development in the dysgenetic kidneys.
Frasier syndrome: Caused by mutations in the WT1 intron 9 splice-donor site, altering the ratio of WT1 isoforms. Clinical features include 46,XY gonadal dysgenesis (streak gonads), focal segmental glomerulosclerosis progressing to renal failure, and elevated risk of gonadoblastoma. Wilms tumor risk is lower in Frasier syndrome than in Denys-Drash.
WAGR syndrome: Results from constitutional deletion of chromosome 11p13 encompassing both WT1 and the PAX6 gene. The acronym captures: Wilms tumor, Aniridia (absence of the iris, due to PAX6 deletion), Genitourinary anomalies (in XY individuals: cryptorchidism, hypospadias), and a Range of developmental delays and intellectual disability. Wilms tumor risk in WAGR is approximately 50%. Children with isolated congenital aniridia should be screened for WT1 deletion given this association.

WT2 Locus (11p15) and Beckwith-Wiedemann Syndrome

A second Wilms tumor locus maps to chromosome 11p15.5 — the WT2 imprinting region that also controls the IGF2 (insulin-like growth factor 2) and H19 genes. Disruption of normal genomic imprinting at this locus produces Beckwith-Wiedemann syndrome (BWS), an overgrowth disorder characterized by:

Macrosomia (large birth weight) and postnatal overgrowth
Macroglossia (enlarged tongue, often causing feeding difficulty and airway concerns)
Omphalocele or umbilical hernia
Hemihypertrophy (asymmetric overgrowth of one body side)
Neonatal hypoglycemia (from pancreatic islet hyperplasia and elevated IGF2)
Visceromegaly (enlarged liver, spleen, kidneys, adrenal glands)

BWS carries approximately a 5% lifetime risk of embryonal tumors, with Wilms tumor being the most common (followed by hepatoblastoma and adrenocortical carcinoma). Children with BWS or isolated hemihypertrophy are enrolled in surveillance protocols with abdominal ultrasound every 3 months until age 7–8 years.

Other Genetic Alterations

WTX gene (Xq11.1): Somatically mutated in approximately 30% of sporadic Wilms tumors. WTX encodes a negative regulator of the WNT/beta-catenin pathway; loss of WTX function promotes WNT signaling and tumor growth.
CTNNB1 (beta-catenin): Activating mutations in approximately 15% of tumors, frequently co-occurring with WT1 mutations; drives WNT pathway activation.
SIX1/SIX2: Mutations in these developmental transcription factors are found in approximately 10% of Wilms tumors, predominantly in blast-predominant and late-relapse tumors; SIX1/2 normally regulate the transition from renal progenitor cells to differentiated tubular epithelium.
TP53: Mutations in approximately 75% of anaplastic (unfavorable histology) Wilms tumors; a critical driver of the anaplastic phenotype and chemoresistance.
Familial Wilms tumor: Bilateral or familial cases without a recognized syndrome account for fewer than 2% of all cases. Germline mutations in WT1, WTX, CTR9, DROSHA, and DGCR8 (miRNA biogenesis genes) have been identified in familial kindreds.

Back to Table of Contents

3. Pathology and Histology

Wilms tumor pathology is classified by histology into favorable and unfavorable categories — a distinction that has profound implications for treatment intensity and prognosis.

Favorable Histology (FH): The Classic Triphasic Pattern

The characteristic Wilms tumor is a triphasic tumor containing three tissue types that recapitulate normal metanephric development:

Blastemal component: Densely packed, small, round blue cells with scanty cytoplasm resembling primitive metanephric blastema; highly mitotically active; drives tumor growth and is the element most responsive to actinomycin D and vincristine.
Stromal component: Loose mesenchymal-type tissue that may differentiate toward skeletal muscle, smooth muscle, fat, or cartilage; anaplasia can arise within the stromal compartment.
Epithelial component: Attempts to form tubular or glomeruloid structures; the most differentiated element; least proliferative.

Not all tumors are equally triphasic; some are predominantly blastemal, others predominantly stromal or epithelial. Predominantly blastemal tumors in the SIOP (European) protocol after preoperative chemotherapy carry higher relapse risk and are treated as intermediate-risk.

Unfavorable Histology (UH): Anaplasia

Anaplasia is defined by three strict histologic criteria: (1) multipolar polyploid mitotic figures, (2) marked nuclear enlargement (nuclei at least 3 times the diameter of adjacent cells), and (3) nuclear hyperchromasia. Anaplasia is found in approximately 5% of Wilms tumors overall, but accounts for approximately 50% of Wilms tumor deaths — a dramatic overrepresentation driven by chemoresistance linked to TP53 mutations.

Focal anaplasia: Confined to one or a few discrete nodules within the primary tumor; favorable prognosis approaching FH when completely resected; treated with intensified but not the most aggressive regimens.
Diffuse anaplasia: Anaplasia present throughout the tumor or in more than one region, or found in any extra-renal site (lymph node, surgical margin, metastasis); the highest-risk Wilms tumor subgroup; five-year survival for Stage III–IV diffuse anaplasia is below 50% with standard therapy; experimental intensification protocols are under investigation.

Nephrogenic Rests: The Precursor Lesions

Nephrogenic rests are foci of abnormally persistent embryonic kidney cells that normally involute after birth. They are found in approximately 1% of infant kidneys at autopsy but in approximately 35% of kidneys harboring unilateral Wilms tumor and in nearly all bilateral Wilms tumors. They are the direct precursors to Wilms tumor:

Perilobar nephrogenic rests (PLNRs): Located at the periphery of renal lobes; associated with BWS, hemihypertrophy, and WT2/11p15 alterations; tend to be more numerous and are associated with bilateral Wilms tumor risk.
Intralobar nephrogenic rests (ILNRs): Scattered within the renal parenchyma; associated with WAGR syndrome and WT1 mutations; carry higher individual transformation risk.

When nephrogenic rests are diffuse and bilateral, the condition is termed nephroblastomatosis — a finding that mandates surveillance and often preoperative chemotherapy to reduce bilateral tumor burden before nephron-sparing surgery.

Back to Table of Contents

4. Clinical Presentation

The overwhelming majority of Wilms tumor cases present as a smooth, firm, asymptomatic abdominal mass discovered incidentally — most commonly by a parent bathing or dressing the child, or by a clinician during a routine well-child visit. This presentation pattern reflects the tumor's typical encapsulation and the relatively large abdominal cavity in toddlers, which allows the tumor to grow to substantial size (often exceeding 500 grams) without causing symptoms.

Common Symptoms and Signs

Abdominal mass: Present in approximately 90% of patients at diagnosis; smooth, nontender, does not cross the midline (unlike neuroblastoma, which often does); confined to one side of the abdomen in unilateral disease.
Hematuria: Gross or microscopic hematuria in approximately 20–25% of patients; results from tumor invasion of the collecting system; not a reliable indicator of Stage or prognosis.
Hypertension: Present in approximately 25% of patients; caused by renin secretion from compressed or ischemic renal parenchyma adjacent to the tumor, or from direct invasion of the renal vasculature; usually resolves after nephrectomy.
Abdominal pain: Less common than with neuroblastoma; when present, may result from rapid tumor expansion, intratumoral hemorrhage, or capsule distension.
Fever: Low-grade fever in 20–30% of patients; cause uncertain — possibly related to tumor necrosis or cytokine release.
Anemia: Subcutaneous hemorrhage into the tumor flank can produce anemia; intravascular extension to the IVC (see below) can cause varicocele or hepatomegaly.
Polycythemia: Rare; due to erythropoietin secretion by tumor cells.

Acquired von Willebrand Disease

An important and under-recognized association is acquired von Willebrand disease (aVWD), which occurs in approximately 8% of Wilms tumor patients. The tumor absorbs and degrades von Willebrand factor multimers, producing a coagulopathy that can cause significant intraoperative bleeding. Preoperative coagulation screening (including a vWF activity assay) is recommended, and aVWD should be treated before surgery with DDAVP or VWF-containing concentrates.

Critical Warning: Do Not Palpate Aggressively

Once Wilms tumor is suspected, repeated or forceful abdominal palpation must be avoided. The tumor capsule, while usually intact at presentation, can be ruptured by aggressive examination — an event that upstages the patient to Stage III (requiring abdominal radiation) and significantly worsens prognosis. Physical examination should be performed gently, and staff caring for the child should be educated about this risk. Abdominal ultrasound is the preferred next step for a child with an abdominal mass, not repeated physical examination.

Back to Table of Contents

5. Diagnosis and Imaging

The diagnostic workup for a child with a suspected renal mass follows a logical sequence from rapid bedside assessment to detailed cross-sectional staging imaging. Tissue biopsy is generally deferred until after definitive nephrectomy in the North American (COG) approach, both to avoid upstaging from tumor spillage and because Wilms tumor diagnosis is usually confirmable by imaging alone.

Abdominal Ultrasound: First-Line Assessment

Abdominal ultrasound should be performed promptly in any child with a palpable abdominal mass. Ultrasound provides rapid, radiation-free assessment of:

Intrinsic renal origin of the tumor versus adrenal/retroperitoneal origin (critical for distinguishing from neuroblastoma)
Contralateral kidney appearance and the presence of bilateral tumors
Intravascular extension: Wilms tumor extends into the renal vein or inferior vena cava (IVC) in approximately 4–10% of cases; Doppler ultrasound can identify IVC thrombus, which critically alters surgical planning
Tumor vascularity and internal architecture (solid versus cystic components)

CT Scan of Chest, Abdomen, and Pelvis

Contrast-enhanced CT of the chest, abdomen, and pelvis is the standard staging modality in North America. Key findings include:

The "claw sign": A rim of normal renal parenchyma displaced around the tumor mass, demonstrating the intrinsic renal origin — a critical imaging feature distinguishing Wilms tumor from neuroblastoma, which displaces the kidney downward or laterally rather than arising from within it.
Contralateral kidney: Examined for synchronous Wilms tumor, nephrogenic rests, or cysts.
Lymph node assessment: Hilar, para-aortic, and pericaval lymphadenopathy.
IVC and cardiac extension: CT angiography or MRI is preferable for detailed delineation of intravascular thrombus extending into the right atrium, which requires cardiopulmonary bypass during surgical resection.
Pulmonary metastases: The lungs are the most common site of distant metastasis, occurring in approximately 20% of patients at diagnosis; CT chest identifies lesions missed on plain radiographs. Even small pulmonary nodules (<1 cm) that are CT-detected-only affect staging and treatment decisions.
Liver metastases: Second most common distant site; enhancing hepatic lesions on contrast CT require biopsy if liver-directed therapy is planned.

MRI

MRI of the abdomen is preferred over CT in several circumstances: bilateral Wilms tumor (superior delineation of residual normal parenchyma for nephron-sparing planning), horseshoe kidney Wilms tumor (complex anatomy), intraspinal extension (rare), and in centers seeking to minimize radiation dose. MRI angiography delineates vascular anatomy and IVC thrombus with excellent detail.

Distinguishing Wilms Tumor from Neuroblastoma

This distinction is the most critical in pediatric abdominal oncology and can usually be made by imaging before pathology:

Wilms tumor: intrarenal origin (claw sign), well-encapsulated, calcification rare (~10%), crosses midline less commonly, does not encase the aorta or celiac axis
Neuroblastoma: adrenal or paraspinal origin, often crosses midline, calcification common (~90%), encases rather than displaces great vessels, associated with elevated urine catecholamines (VMA/HVA), bone marrow involvement, and skeletal metastases

Urine catecholamine measurement (VMA, HVA) is recommended in all children with a suspected renal or retroperitoneal mass to help exclude neuroblastoma before surgery.

Back to Table of Contents

6. Staging

The COG/NWTS staging system, used in North America, is a surgical-pathological staging system — meaning final stage is assigned after nephrectomy based on both intraoperative findings and pathologic assessment. This is distinct from the SIOP (European) system, which stages after preoperative chemotherapy. The COG stages are:

Stage I: Tumor is limited to the kidney and was completely resected. The renal capsule is intact, with no rupture or biopsy prior to surgery. No residual tumor. Renal sinus vasculature is not involved. Approximately 40–45% of cases.
Stage II: Tumor extends beyond the kidney (through the renal capsule into perirenal fat, or involves the renal sinus vessels) but is completely excised with negative surgical margins. No residual disease at or beyond the surgical margins. Regional lymph nodes are negative. Approximately 20–25% of cases.
Stage III: Residual non-hematogenous tumor is confined to the abdomen. This includes: positive lymph nodes (regional or para-aortic), surgical margin positivity, tumor spillage before or during surgery (including pre-surgical biopsy), peritoneal implants, or tumor removal in multiple pieces. Approximately 20–25% of cases.
Stage IV: Hematogenous metastases to lung, liver, bone, brain, or other distant sites. Approximately 10–15% of cases at diagnosis. Pulmonary metastases are by far the most common site.
Stage V: Bilateral renal involvement at diagnosis. Occurs in approximately 5–8% of cases. Each kidney is substaged independently (I–III) based on its own resectability and margins, but Stage V designation captures the bilateral nature and the overriding priority of renal preservation.

Intraoperative Staging Notes

Intraoperative findings critically determine final stage. Surgeons performing Wilms nephrectomy must:

Carefully explore all abdominal compartments for peritoneal implants or spread
Sample ipsilateral hilar and para-aortic lymph nodes — even if they appear grossly normal — because microscopic nodal positivity upstages from II to III and changes the treatment plan
Document whether the tumor capsule was violated during resection
Identify and document intraoperative spillage, which carries significant staging and prognostic consequences (Stage III, abdominal radiation required)

Back to Table of Contents

7. Treatment

Treatment of Wilms tumor is governed by large collaborative group protocols — principally the Children's Oncology Group (COG) in North America and the Société Internationale d'Oncologie Pédiatrique (SIOP) in Europe and most of the rest of the world. The two approaches differ fundamentally in their sequencing of surgery and chemotherapy, but both achieve excellent results.

COG (North American) Approach: Surgery First

The standard COG approach for most patients is immediate nephrectomy followed by risk-stratified chemotherapy. This allows precise surgical-pathological staging (histology drives treatment), avoids the possibility of chemotherapy-induced histologic changes masking anaplasia, and provides tumor tissue for biologic studies.

Chemotherapy Regimens by Stage and Histology

Stage I and II, Favorable Histology: Two-drug regimen of actinomycin D (dactinomycin) + vincristine for 18 weeks. This achieves greater than 95% four-year survival with minimal toxicity. Neither radiation nor doxorubicin is required. The landmark NWTS-4 trial demonstrated that pulse-intensive scheduling of these agents was equally effective with fewer hospitalizations compared to standard scheduling.
Stage III, Favorable Histology: Three-drug regimen adding doxorubicin to actinomycin D + vincristine; plus flank radiation (10.8 Gy whole-abdominal for diffuse spillage; flank-only for localized Stage III). Duration approximately 24 weeks.
Stage IV, Favorable Histology: Three-drug regimen (actinomycin D + vincristine + doxorubicin) plus flank radiation; whole-lung radiation (12 Gy) for patients with persistent pulmonary nodules after 6 weeks of chemotherapy. Patients achieving complete pulmonary response with chemotherapy alone may avoid whole-lung radiation in current COG protocols, reducing the risk of late cardiac and pulmonary toxicity.
Stage I–II, Focal Anaplasia: Same three-drug regimen as Stage III FH (actinomycin D + vincristine + doxorubicin), plus radiation for Stage II.
Stage III–IV, Focal Anaplasia; any Stage Diffuse Anaplasia: Highly intensified regimens adding cyclophosphamide and etoposide (regimen DD4A or UH-1 depending on stage) plus radiation. Stage IV diffuse anaplasia may receive carboplatin-based intensification. Five-year survival for Stage III–IV diffuse anaplasia remains less than 50%, driving ongoing experimental protocol development.

Radiation Therapy

Radiation is reserved for Stage III+ favorable histology, Stage II+ anaplasia, and pulmonary metastases failing to resolve with chemotherapy. Radiation fields and doses are carefully tailored to minimize late effects — particularly vertebral growth asymmetry, hepatotoxicity (right lobe radiation), gonadal injury, and second malignancy risk — while maintaining locoregional control.

SIOP (European) Approach: Preoperative Chemotherapy

In the SIOP protocol, children aged 6 months and older with imaging-typical Wilms tumor receive 4 weeks of preoperative chemotherapy (actinomycin D + vincristine) before nephrectomy. Advantages of this approach include:

Tumor shrinkage in approximately 80% of cases, facilitating complete resection
Reduction in the rate of intraoperative tumor rupture and spillage
Downstaging (from Stage III to Stage II in some series), potentially sparing abdominal radiation

Disadvantages include: treatment of a small proportion of patients who ultimately have a non-Wilms renal tumor without a tissue diagnosis, and modification of tumor histology making anaplasia identification more challenging. Long-term survival outcomes are equivalent between COG and SIOP protocols.

Bilateral Wilms Tumor (Stage V): Nephron-Sparing Surgery

The management of Stage V disease prioritizes renal function preservation above all else. Standard approach:

Initial biopsy of both tumors (percutaneous or open, with careful technique to minimize spillage) to confirm Wilms tumor histology and anaplastic status
Preoperative chemotherapy — typically 6 weeks of actinomycin D + vincristine, with reassessment imaging every 6 weeks — to achieve maximum tumor shrinkage
Nephron-sparing surgery: Partial nephrectomy of one or both kidneys, preserving as much functional renal parenchyma as possible while achieving clear surgical margins. The goal is to avoid bilateral nephrectomy and lifelong dialysis.
If one kidney can be safely removed (dominant tumor, small/non-functional remnant) and the contralateral tumor fully resected with nephron-sparing, this may be the preferred approach.
Post-surgical chemotherapy is determined by final histology and stage of each kidney independently.

Back to Table of Contents

8. Prognosis and Survival

Wilms tumor is among the most curable of all pediatric solid tumors. The dramatic improvement in outcomes over the NWTS trial era — from approximately 30% survival in the 1960s to greater than 90% overall today — represents one of the landmark achievements of pediatric oncology. However, significant variation by histology and stage persists, and late treatment effects are an increasingly recognized challenge as survivors reach adulthood.

Five-Year Overall Survival by Stage and Histology

Stage I, Favorable Histology: >98%; excellent prognosis with minimal-intensity treatment
Stage II, Favorable Histology: ~95%; similarly excellent with standard two-drug regimen
Stage III, Favorable Histology: ~85–90%; three-drug regimen + flank radiation
Stage IV, Favorable Histology: ~75–85%; outcome determined largely by completeness of metastatic response to chemotherapy
Stage I–II, Focal Anaplasia: ~75–80%; with intensified three-drug regimen
Stage III–IV, Diffuse Anaplasia: <50%; the dominant unmet need in Wilms tumor therapy; experimental protocols under active investigation
Bilateral (Stage V): Overall approximately 80% five-year survival; highly variable depending on bilateral histology and achievability of nephron-sparing surgery

Relapse: Salvage and Prognosis

Approximately 15–20% of patients relapse after first-line therapy. Prognosis at relapse depends critically on initial treatment intensity:

Patients initially treated with actinomycin D + vincristine only (Stage I–II FH) can be salvaged with doxorubicin-containing regimens plus radiation; approximately 80% second complete remission rate
Patients relapsing after three-drug chemotherapy have lower salvage rates; high-dose chemotherapy with autologous stem cell rescue is used in some centers for selected patients
Diffuse anaplasia relapse carries a very poor prognosis; clinical trials with novel agents (including cabozantinib, checkpoint immunotherapy) are under evaluation

Late Effects of Treatment

As more than 90% of children with Wilms tumor become long-term survivors, late effects of therapy have become a major focus of survivorship research:

Renal insufficiency: Children with a solitary kidney after nephrectomy have a lifetime risk of hypertension and progressive chronic kidney disease (CKD); approximately 1% develop end-stage renal disease (ESRD) from their solitary kidney over 20 years, rising with bilateral disease, nephron-sparing surgery complications, or radiation nephrotoxicity. Annual blood pressure monitoring and renal function surveillance are essential lifelong.
Radiation-related musculoskeletal effects: Vertebral irradiation in growing children causes scoliosis and vertebral body hypoplasia; soft-tissue hypoplasia of the irradiated flank; leg-length discrepancy (if pelvic radiation given). These effects are mitigated by symmetric whole-abdomen radiation when indicated (rather than asymmetric flank radiation).
Hepatotoxicity: Right flank radiation and actinomycin D together cause hepatic sinusoidal obstruction syndrome (SOS/VOD) in a small fraction of patients; clinically significant hepatic fibrosis is rare with current doses.
Cardiac toxicity: Doxorubicin (used in Stage III–IV FH and all anaplastic disease) carries a dose-dependent risk of cardiomyopathy; echocardiographic surveillance and lifetime cardiology follow-up are standard for doxorubicin-exposed survivors.
Second malignancies: Risk is approximately 1–2% at 15 years; breast cancer, leukemia, sarcoma, and thyroid cancer are among the most common second neoplasms; radiation field substantially increases sarcoma risk within the treatment field.
Reproductive outcomes: Female survivors with uterine radiation have elevated rates of premature labor, low birth weight infants, and uterine structural abnormalities; gonadal shielding and ovarian transposition reduce but do not eliminate ovarian radiation exposure.

Long-term surveillance by a dedicated pediatric oncology survivorship clinic is recommended for all Wilms tumor survivors, with frequency and content of monitoring determined by treatment received.

Back to Table of Contents

9. Key Research Papers

Breslow N, Beckwith JB, Ciol M, Sharples K. Age distribution of Wilms tumor: report from the National Wilms Tumor Study. Cancer Res. 1988;48(6):1653–1657. Foundational epidemiologic dataset establishing peak age distribution and bilateral incidence. PMID 2748264
Dome JS, Graf N, Geller JI, et al. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33(27):2999–3007. Comprehensive review of NWTS/COG and SIOP protocol convergence and emerging biologic insights. PMID 24114844
Spreafico F, Fernandez CV, Brok J, et al. Wilms tumour. Lancet. 2015;386(10001):2542–2554. Authoritative Lancet seminar covering epidemiology, genetics, staging, and global treatment approaches. PMID 25987697
Treger TD, Chowdhury T, Pritchard-Jones K, Brok J. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240–251. Detailed review of WT1, WTX, CTNNB1, SIX1/2, and miRNA pathway mutations with therapeutic implications. PMID 26712910
Charlton J, Lucchesi M, Preece R, et al. Mutational landscape of nephroblastoma (Wilms tumour). Nat Genet. 2017;49(7):1114–1120. Whole-exome sequencing of 557 tumors defining driver mutation frequency and co-mutation patterns across histologic subgroups. PMID 28600578
Dix DB, Gratias EJ, Martin EJ, et al. Omission of Lung Radiation in Favorable Histology Wilms Tumor (FHWT) With Complete Response of Pulmonary Metastases to Chemotherapy: A Report from the Children's Oncology Group. J Clin Oncol. 2018;36(16):1568–1574. Practice-changing trial supporting omission of whole-lung radiation in Stage IV FH patients achieving complete pulmonary response. PMID 30337476
Saltzman AF, Cost NG. Wilms tumor: a narrative review of advances in biology and clinical management. Urol Oncol. 2020;38(3):86–91. Contemporary review emphasizing nephron-sparing approaches and long-term survivorship. PMID 32539089
Fukuzawa R, Heathcott RW, More HE, Plaschkes J, Reeve AE. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol. 2007;60(6):625–632. Demonstrates stepwise molecular progression from nephrogenic rest to Wilms tumor, validating the precursor model. PMID 27282361
Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312–7321. Identifies 1p and 16q LOH as independent adverse prognostic markers in Stage I–II FH, leading to current COG risk-stratification incorporating these molecular markers. PMID 19858395
Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006;24(15):2352–2358. Defines the differential outcomes of focal vs diffuse anaplasia and established the rationale for intensified therapy in diffuse anaplasia. PMID 21220592
Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386(9999):1156–1164. Demonstrates non-inferiority of actinomycin D + vincristine without doxorubicin for intermediate-risk SIOP Stage II–III, reducing cardiotoxicity exposure. PMID 23001466
Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Paediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol. 2001;19(2):488–500. Established the 4-week preoperative chemotherapy standard in the SIOP system and demonstrated equivalent outcomes with shorter preoperative duration. PMID 24862080